The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein

Enrolling by invitation

Phase 4 Results N/A

Summary of Purpose

In order to reevaluate safety and efficacy of human urinary kallikrein in treating acute cerebral infarction ,a multi-center, open label , single group study was designed. Expect to enroll 60 sites and 2186 subjects. Subjects will receive kallikrein treatment according to real clinical practice (suggest above 14days treatment) and 90 days follow up

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 18 June 2017.

1 Aug 2015 10 Sep 2015 30 Nov 2018 30 Nov 2018 1 Jun 2017 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Conditions

Sponsors

Trial Design

  • Masking: Open Label
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Single Group Assignment

Contacts

Not available